Amend Surgical received FDA 510(k) clearance to market NanoFUSE® BA as a bone graft extender for spine and orthopaedic applications.
The bioactive glass-based product represents the second FDA-cleared product for Amend, the first being NanoFUSE DBM, for which worldwide licensing rights were granted to Amend Surgical by Nanotherapeutics.
Amend Surgical’s development pipeline includes novel clinically-evaluated osteoinductive bone extracts.
Amend Surgical received FDA 510(k) clearance to market NanoFUSE® BA as a bone graft extender for spine and orthopaedic applications.
The bioactive glass-based product represents the second FDA-cleared product for Amend, the first being NanoFUSE DBM, for which worldwide licensing rights were granted to Amend Surgical by Nanotherapeutics. ...
Amend Surgical received FDA 510(k) clearance to market NanoFUSE® BA as a bone graft extender for spine and orthopaedic applications.
The bioactive glass-based product represents the second FDA-cleared product for Amend, the first being NanoFUSE DBM, for which worldwide licensing rights were granted to Amend Surgical by Nanotherapeutics.
Amend Surgical’s development pipeline includes novel clinically-evaluated osteoinductive bone extracts.
Copy to clipboard 
